[en] BACKGROUND: The aim was to ascertain the 1-year clinical outcomes of 1,234 patients who underwent implantations of sirolimus-eluting stents (SES) for acute myocardial infarction (MI) in the multinational e-SELECT registry. METHODS: Fifteen thousand and one hundred and forty-seven patients treated with SES were entered in the e-SELECT registry, of whom 1,234 presented within <24 hours of onset of acute MI. RESULTS: At 1 year, the rates of major adverse cardiac events (MACE) (5.5% vs. 4.8%; P = 0.28) were similarly low in the acute and no acute MI groups. The rates of definite/probable stent thrombosis (ST) were higher in the acute MI group (2.1%vs; 0.88%, P < 0.001). ST was a strong independent predictor of death at 1 year (HR 13.4; 95% CI 5.0, 36.0; P < 0.001) and MI (HR 58.9; 95% CI 26.9, 129.1; P < 0.001). Dual antiplatelet therapy (DAPT) compliance at 6 months was 96.0% in the acute MI versus 94.5% in the no acute MI group (P = 0.03). CONCLUSION: In selected patients presenting within <24 hours of acute MI onset and highly compliant with DAPT, SES implantation was associated with similar rates of MACE, though higher rates of ST, as compared to no acute MI patients.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Worthley, Stephen G.
Abizaid, Alexandre
Banning, Adrian
Bartorelli, Antonio
Dzavik, Vladimir
Ellis, Stephen
Gao, Runlin
Legrand, Victor ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie
Urban, Philip
Spaulding, Christian
Language :
English
Title :
One-year clinical outcomes after sirolimus-eluting coronary stent implantation for acute myocardial infarction in the worldwide e-SELECT registry.
Antman EM, Hand M, Armstrong PW, et al. 2004 Writing Committee Members, Anbe DT, Kushner FG, Ornato JP, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Halperin JL, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296-329.
Anderson JL, Adams CD, Antman EM, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association ofCardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304.
Valgimigli M, Percoco G, Malagutti P, et al. STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: A randomized trial. JAMA 2005;293:2109-2117. (Pubitemid 40617063)
Spaulding C, Henry P, Teiger E, et al.TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006;355:1093-1104. (Pubitemid 44394916)
Menichelli M, Parma A, Pucci E, et al. Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). J Am Coll Cardiol 2007;49: 1924-1930. (Pubitemid 46694284)
Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006;355:1105-1113. (Pubitemid 44394917)
Stone GW, Lansky AJ, Pocock SJ, et al. HORIZONSAMI Trial Investigators. Paclitaxel-eluting stents versus bare metal stents in acute myocardial infarction. N Engl J Med 2009;360:1946-1959.
Urban P, Abizaid A, Banning A, et al. for the e-SELECT investigators. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population. A report from the e-SELECT registry. J Am Coll Cardiol 2011;57:1445-1454.
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383. (Pubitemid 17055592)
Cutlip DE, Windecker S, Mehran R, et al. Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344-2351. (Pubitemid 46685903)
Montalescot G, Gallo R, White HD, et al. STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355:1006-1017. (Pubitemid 44343544)
Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007;28:2706-2713. (Pubitemid 350139205)
Valgimigli M, Percoco G, Malagutti P, et al. STRATEGY Investigators. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: A randomized trial. JAMA 2005;293:2109-2117. (Pubitemid 40617063)
Di Lorenzo E, Sauro R, Varricchio A, et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: Four year results of the Paclitaxel or sirolimus-eluting stent vs bare metal stent in primary angioplasty (PASEO) randomized trial. Am Heart J 2009;158:e43-50.
Spaulding C, Teiger E, Commeau P, et al. Four-year followup of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC Cardiovasc Interv 2011;4:14-23.
Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or baremetal stents for acute myocardial infarction. N Engl J Med 2008;359:1330-1342.
Steg PG, Fox KA, Eagle KA, et al. Global Registry of Acute Coronary Events (GRACE) Investigators. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 2009;30:321-329.
Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007;369(9562):667-678. (Pubitemid 46281313)
Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029. (Pubitemid 46376802)
Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: Incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 2009;30:2714-2721.
Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007;115:2435-2441. (Pubitemid 46717966)
Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27:1500-1510. (Pubitemid 46986103)
Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation 2008;118:1138-1145.
Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006;113:2803-2809. (Pubitemid 44305292)
Van de Werf F, Bax J, Betriu A, et al. ESC Committee for Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008;29:2909-2945.
Urban P, Gershlick AH, Guagliumi G, et al. e-Cypher Investigators. Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry. Circulation 2006;113:1434-1441. (Pubitemid 43739440)
Montalescot G, Wiviott SD, Braunwald E, et al. TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 2009;373(9665):723-731.
Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015. (Pubitemid 350106708)
Leibundgut G, Nietlispach F, Pittl U, et al. Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina-comparison of the effects of drug-eluting versus bare-metal stents. Am Heart J 2009;158:271-276.
Kukreja N, OnumaY,Garcia-Garcia HM, et al. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. J Am Coll Cardiol Interv 2009;2: 534-541.
Holmes D, Kereiakes D, Garg S, et al. Stent thrombosis. J Am Coll Cardiol 2010;56;1357-1313.
Cook S,Windecker S. Early stent thrombosis: Past, present and future. Circulation 2009;119:657-659.
Van Werkum JW, Heestermans AA, Zomer AC. Predictors of coronary stent thrombosis. J Am Coll Cardiol 2009;53:1399-1409.
Amoroso G, van Geuns RJ, Spaulding C, et al. Assessment of the safety and performance of the STENTYS self-expanding coronary stent in acute myocardial infarction: Results from the APPOSITION I study. EuroIntervention 2011;7:428-436.
Lotan C, Meredith IT, Mauri L, et al. E-Five Investigators. Safety and effectiveness of the Endeavor zotarolimuseluting stent in real-world clinical practice: 12-month data from the E-Five registry. JACC Cardiovasc Interv 2009;2:1227-1235.
Lasala JM, Cox DA, Dobies D, et al. ARRIVE 1 and ARRIVE 2 Participating Physicians. Drug-eluting stent thrombosis in routine clinical practice: Two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv 2009;2:285-293.
